Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Based on an average trading volume of 3,880,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.0% of the shares of the company are short sold.
Institutional Trading of Candel Therapeutics
A number of large investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new stake in Candel Therapeutics in the 2nd quarter worth approximately $2,408,000. Citigroup Inc. bought a new stake in Candel Therapeutics in the 2nd quarter worth approximately $149,000. Vanguard Group Inc. lifted its position in Candel Therapeutics by 5.4% in the 4th quarter. Vanguard Group Inc. now owns 425,749 shares of the company’s stock worth $626,000 after buying an additional 21,680 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Candel Therapeutics in the 1st quarter worth approximately $28,000. Finally, BlackRock Inc. lifted its position in Candel Therapeutics by 15.5% in the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company’s stock worth $674,000 after buying an additional 17,708 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.
Candel Therapeutics Stock Performance
CADL traded up $0.07 during trading hours on Tuesday, hitting $5.89. The stock had a trading volume of 1,072,389 shares, compared to its average volume of 4,517,694. The company’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $1.52. Candel Therapeutics has a 1 year low of $0.66 and a 1 year high of $11.40. The stock has a market cap of $172.87 million, a PE ratio of -4.76 and a beta of 0.92. The company has a quick ratio of 2.59, a current ratio of 2.59 and a debt-to-equity ratio of 0.97.
Candel Therapeutics Company Profile
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Further Reading
- Five stocks we like better than Candel Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Silicon Motion Proves That AI in Motion Stays in Motion
- What Are Dividend Achievers? An Introduction
- Undervalued UnitedHealth Group Won’t Be For Long
- What is the Hang Seng index?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.